title: High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
abstract: OBJECTIVE
  We determined the toxicity and efficacy of a new preparative autologous bone marrow transplantation (ABMT) regimen in patients with relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's disease.
  
  
  METHODS
  Forty-four non-Hodgkin's lymphoma and 35 Hodgkin's disease patients 16 to 63 years of age were given intravenous carmustine (BCNU) 600 to 1,050 mg/m2, etoposide 2,400 to 3,000 mg/m2, and cisplatin 200 mg/m2 (BEP) and ABMT. Fifty-nine patients also received 15 to 20 Gy local radiation (involved-field radiotherapy [RI]) to active or previously bulky (> 5 cm) disease sites.
  
  
  RESULTS
  Nonhematologic toxicities included nausea, vomiting, high-tone hearing loss, stomatitis, esophagitis, diarrhea, and hepatic and pulmonary toxicity. Two patients died within 40 days of marrow infusion as a result of sepsis and one patient died 7 months after transplant as a result of pulmonary fibrosis. Complete remissions (CRs) were noted in 72% (n = 57) of patients (n = 33 non-Hodgkin's lymphoma; n = 24 Hodgkin's disease). Forty patients (51%) remained alive and disease-free (n = 24 non-Hodgkin's lymphoma; n = 16 Hodgkin's disease) at a median of 17 (range, 8 to 57) months after marrow reinfusion.
  
  
  CONCLUSIONS
  This regimen seems to be effective for relapsed lymphoma patients whose disease continues to exhibit chemotherapy sensitivity (16 of 24 [67%] disease-free). Furthermore, this regimen seems to be effective in patients who have never attained a CR (seven of 19 [37%] disease-free).
authors.affiliation: Department of Medicine, Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, OH 44106.
authors.forename: H M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: P
authors.initials: P
authors.lastname: Crilley
authors.forename: N
authors.initials: N
authors.lastname: Ciobanu
authors.forename: R J
authors.initials: RJ
authors.lastname: Creger
authors.forename: R M
authors.initials: RM
authors.lastname: Fox
authors.forename: D C
authors.initials: DC
authors.lastname: Shina
authors.forename: S I
authors.initials: SI
authors.lastname: Bulova
authors.forename: R
authors.initials: R
authors.lastname: Gucalp
authors.forename: B W
authors.initials: BW
authors.lastname: Cooper
authors.forename: D
authors.initials: D
authors.lastname: Topolsky
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008875:Middle Aged; D012008:Recurrence; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D002945:Cisplatin; D002330:Carmustine